PTC Therapeutics Inc (NASDAQ:PTCT)

47.60
Delayed Data
As of Apr 09
 -0.66 / -1.37%
Today’s Change
43.65
Today|||52-Week Range
70.82
-22.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.5B

Company Description

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Contact Information

PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield New Jersey 07080-2449
P:(908) 222-7000
Investor Relations:

Employees

Shareholders

Mutual fund holders70.14%
Other institutional35.25%
Individual stakeholders12.35%

Top Executives

Stuart Walter PeltzChief Executive Officer & Director
Emily HillChief Financial Officer
Neil Gregory AlmsteadChief Technical Operations Officer
Mark Jerome PykettChief Scientific Officer
Mark Elliott BouldingChief Legal Officer & Executive Vice President